Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

Apabetalone (RVX-208) is an epigenetic regulator developed to treat cardiovascular disease (CVD) that targets BET proteins. Through transcriptional regulation RVX-208 modulates pathways that underlie CVD including reverse cholesterol transport, vascular inflammation, coagulation, and complement. Usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Calosing, Cyrus, Jahagirdar, Ravi, Johansson, Jan, Sweeney, Michael, Wong, Norman C., Kulikowski, Ewelina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585290/
https://www.ncbi.nlm.nih.gov/pubmed/28567671
http://dx.doi.org/10.1007/s12265-017-9755-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585290/
https://www.ncbi.nlm.nih.gov/pubmed/28567671
http://dx.doi.org/10.1007/s12265-017-9755-z

Ejemplares similares